Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomised, Open Label, Parallel Group Phase II Study Comparing the Efficacy and Tolerability of BIBF 1120 Versus Sunitinib in Previously Untreated Patients With Renal Cell Cancer
Brief Summary: Compare safety and efficacy of BIBF 1120 versus sunitinib in patients with advanced RCC and to investigate the effects of BIBF 1120 on the heart rate (HR) corrected QT interval (QTcF).


Options:
A: Arm Label: Alternating regimen; Type: EXPERIMENTAL; Interventions: Drug: Pazopanib, Drug: Everolimus | Arm Label: Sequential treatment; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pazopanib, Drug: Everolimus | Intervention Type: DRUG; Name: Pazopanib; Assigned to Arm(s): Sequential treatment | Intervention Type: DRUG; Name: Everolimus; Assigned to Arm(s): Sequential treatment | Intervention Type: DRUG; Name: Pazopanib; Assigned to Arm(s): Alternating regimen | Intervention Type: DRUG; Name: Everolimus; Assigned to Arm(s): Alternating regimen | Intervention Type: DRUG; Name: Everolimus; Assigned to Arm(s): Alternating regimen | Intervention Type: DRUG; Name: Pazopanib; Assigned to Arm(s): Alternating regimen
B: Arm Label: Rotational arm; Type: EXPERIMENTAL; Interventions: Drug: Sunitinib, Drug: Everolimus | Arm Label: Sequential arm; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sunitinib, Drug: Everolimus | Intervention Type: DRUG; Name: Sunitinib; Assigned to Arm(s): Rotational arm, Sequential arm | Intervention Type: DRUG; Name: Everolimus; Assigned to Arm(s): Rotational arm, Sequential arm
C: Arm Label: Arm A (sunitinib malate, placebo); Type: EXPERIMENTAL; Interventions: Other: Laboratory Biomarker Analysis, Other: Placebo, Other: Quality-of-Life Assessment, Drug: Sunitinib Malate | Arm Label: Arm B (sorafenib tosylate, placebo); Type: EXPERIMENTAL; Interventions: Other: Laboratory Biomarker Analysis, Other: Placebo, Other: Quality-of-Life Assessment, Drug: Sorafenib Tosylate | Arm Label: Arm C (placebo); Type: PLACEBO_COMPARATOR; Interventions: Other: Laboratory Biomarker Analysis, Other: Placebo, Other: Quality-of-Life Assessment | Intervention Type: OTHER; Name: Laboratory Biomarker Analysis; Assigned to Arm(s): Arm A (sunitinib malate, placebo), Arm B (sorafenib tosylate, placebo), Arm C (placebo) | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Arm A (sunitinib malate, placebo), Arm B (sorafenib tosylate, placebo), Arm C (placebo) | Intervention Type: OTHER; Name: Quality-of-Life Assessment; Assigned to Arm(s): Arm A (sunitinib malate, placebo), Arm B (sorafenib tosylate, placebo), Arm C (placebo) | Intervention Type: DRUG; Name: Sorafenib Tosylate; Assigned to Arm(s): Arm B (sorafenib tosylate, placebo) | Intervention Type: DRUG; Name: Sunitinib Malate; Assigned to Arm(s): Arm A (sunitinib malate, placebo)
D: Arm Label: Nintedanib (BIBF 1120); Type: EXPERIMENTAL; Interventions: Drug: BIBF 1120 | Arm Label: sunitinib; Type: ACTIVE_COMPARATOR; Interventions: Drug: sunitinib | Intervention Type: DRUG; Name: BIBF 1120; Assigned to Arm(s): Nintedanib (BIBF 1120) | Intervention Type: DRUG; Name: sunitinib; Assigned to Arm(s): sunitinib

Answer: D